Halozyme Therapeutics (HALO) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free HALO Stock Alerts $43.08 -0.74 (-1.69%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 4:45 AM | marketbeat.comDimensional Fund Advisors LP Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,613,113 shares of theMay 27 at 4:10 PM | marketbeat.comBernzott Capital Advisors Reduces Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Bernzott Capital Advisors decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,979 shares of the biopharmaceutical company's stMay 26 at 1:20 AM | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) and Entera Bio (NASDAQ:ENTX) Critical AnalysisMay 25 at 4:47 PM | marketbeat.comOntario Teachers Pension Plan Board Buys 19,882 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Ontario Teachers Pension Plan Board lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 137.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,346 shares of the biopharmaceutical company's stMay 24, 2024 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $453,800.00 in StockMay 23, 2024 | insidertrades.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 10,000 Shares of StockMay 23, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO)May 22, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday.May 21, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $2.15 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Assenagon Asset Management S.A. cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 57.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,840 shares of the biopharmaMay 21, 2024 | markets.businessinsider.comHalozyme: Bristol Myers Gets New PDUFA Date For Subcutaneous Nivolumab Co-Formulated With ENHANZEMay 21, 2024 | prnewswire.comHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®May 20, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Lowered by GW&K Investment Management LLCGW&K Investment Management LLC cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,226,538 shares of the biopharmaceutical company'sMay 19, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Mizuho Markets Americas LLCMizuho Markets Americas LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 446,661 shares of tMay 18, 2024 | marketbeat.comWafra Inc. Acquires 23,811 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Wafra Inc. grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,877 shares of the biopharmaceutical company's stock after purchasing an addiMay 17, 2024 | marketbeat.comInternational Assets Investment Management LLC Buys New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 27,868 shares of the biopharmaceutical company's stock, valued at approximateMay 16, 2024 | finance.yahoo.comHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS RatingMay 16, 2024 | marketbeat.comBoston Partners Purchases 468,977 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Boston Partners increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 562.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 552,392 shares of the biopharmaceutical company'sMay 14, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High at $45.15Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $45.15May 13, 2024 | marketbeat.comSwiss National Bank Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Swiss National Bank decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 260,000 shares of the biopharmaceutical company'sMay 11, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Position Raised by Mesirow Institutional Investment Management Inc.Mesirow Institutional Investment Management Inc. raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 453,827 shareMay 10, 2024 | finance.yahoo.comBiotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled BreakoutMay 10, 2024 | marketbeat.comCwm LLC Cuts Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Cwm LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 97.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,113 shares of the biopharMay 9, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in May 2024May 9, 2024 | seekingalpha.comHalozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | washingtonpost.comThe Trade Desk: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Trading Up 5.9%Halozyme Therapeutics (NASDAQ:HALO) Shares Up 5.9%May 8, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) PT Lowered to $71.00 at JMP SecuritiesJMP Securities cut their target price on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a "market outperform" rating for the company in a research note on Wednesday.May 8, 2024 | finance.yahoo.comQ1 2024 Halozyme Therapeutics Inc Earnings CallMay 8, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY 2024 earnings guidance. The company provided EPS guidance of 3.550-3.900 for the period, compared to the consensus estimate of 3.680. The company also issued revenue guidance of $915.0 millionillion-$985.0 millionillion, compared to the consensus estimate of $951.5 millionillion.May 8, 2024 | prnewswire.comHalozyme to Participate in Upcoming Investor ConferencesMay 8, 2024 | finance.yahoo.comHalozyme Therapeutics Inc (HALO) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth ...May 7, 2024 | investorplace.comHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comHalozyme Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | finance.yahoo.comHalozyme Therapeutics Q1 2024 Earnings: Misses EPS Estimates but Shows Revenue GrowthMay 7, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Issues FY24 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY24 earnings guidance. The company provided EPS guidance of $3.55-3.90 for the period, compared to the consensus estimate of $3.52. The company also issued revenue guidance of $915-985 millionillion, compared to the consensus estimate of $954.43 millionillion.May 7, 2024 | seekingalpha.comHalozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | prnewswire.comHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTSMay 7, 2024 | marketbeat.comLSV Asset Management Invests $17.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)LSV Asset Management purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 462,400 shares of the biopharmaMay 5, 2024 | marketbeat.comRussell Investments Group Ltd. Trims Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Russell Investments Group Ltd. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 359,706 shares of the biopharmaceutical compMay 3, 2024 | finance.yahoo.comHow Novo-Catalent Deal Affects Halozyme (HALO)?April 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Halozyme on Strong Technology Prospects and Strategic PartnershipsApril 30, 2024 | marketbeat.comHalozyme Therapeutics (HALO) Set to Announce Earnings on TuesdayHalozyme Therapeutics (NASDAQ:HALO) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587909)April 30, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO)HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday.April 29, 2024 | msn.comSarepta Therapeutics Stock Shows Improved Technical StrengthApril 29, 2024 | msn.comHuonslab applies for clinical trial of hyaluronidase drugApril 25, 2024 | prnewswire.comMahesh Krishnan Elected to Halozyme's Board of DirectorsApril 25, 2024 | markets.businessinsider.comCrossject reports audited financial results for 2023April 25, 2024 | marketbeat.comHandelsbanken Fonder AB Purchases 222,200 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Handelsbanken Fonder AB increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 930.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 246,069 shares of the biopharmaceutical company's stock after buying an additional 222,200 shaApril 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… Click here to see a unique election-year trade HALO Media Mentions By Week HALO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.620.87▲Average Medical News Sentiment HALO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼135▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EXEL News Today RGEN News Today NVAX News Today RLAY News Today ADPT News Today ALLO News Today FATE News Today KOD News Today NBIX News Today RVMD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
